Novo faces delay in US review of haemophilia drug
The FDA has extended its review of Novo's experimental haemophilia A drug denecimig because of ongoing remediation work at a manufacturing facility.
Newsletters and Deep Dive digital magazine
The FDA has extended its review of Novo's experimental haemophilia A drug denecimig because of ongoing remediation work at a manufacturing facility.
Bayer has joined the ranks of pharma groups planning major facility investments in the US, with a $2.2bn plan for a new production unit in Ohio.
Will your launch strategy work once it has finally left the meeting room and met the competition?
CMS has finalised a new drug pricing policy for Medicare that has drawn sharp criticism from the pharma industry.
Two Indian nationals are facing charges relating to the sale of counterfeit versions of Novo's diabetes treatment Ozempic to distributors in the US.
Editor's Picks
Newsletters and Deep Dive
digital magazine